More on ImmunoGen (IMGN): The stock's moving about quite a bit, but currently +3.8% following FDA approval of Kadcyla. The drug is being approved with a Boxed Warning alerting users and prescribers of heart and liver toxicity as well as severe life-threatening birth defects.
More on ImmunoGen (IMGN): The stock's moving about quite a bit, but currently +3.8%...
From other sites
at CNBC.com (Dec 19, 2014)
at CNBC.com (Dec 2, 2014)
at CNBC.com (Sep 8, 2014)
at CNBC.com (Aug 14, 2014)
at CNBC.com (Jun 25, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs